SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
oby20584-sup-0001-suppinfo01.tif1284KFigure S1. LS mean percent weight loss from baseline to week 28 in the ITT-LOCF population. (A) PHEN/TPM ER 15/92 compared with phentermine 15 and topiramate ER 92; (B) PHEN/TPM ER 7.5/46 compared with phentermine 7.5 and topiramate ER 46; and (C) PHEN/TPM ER 7.5/46 compared with phentermine 15 and topiramate ER 92. *P < 0.0001 vs. placebo; P = 0.0001 vs. phentermine 15; P = 0.0009 vs. topiramate ER 92; §P = 0.0003 vs. phentermine 7.5; P < 0.0001 vs. topiramate ER 46; ||P = 0.0037 vs. phentermine 15; #P = 0.0150 vs. topiramate ER 92. ITT, intention- to-treat; LOCF, last observation carried forward; LS, least-squares; PHEN/TPM ER 15/92, phentermine 15 mg and topiramate extended-release 92 mg; PHEN 15, phentermine 15 mg; TPM ER 92, topiramate extended-release 92 mg; PHEN/TPM ER 7.5/46, phentermine 7.5 mg/topiramate extended-release 46 mg; PHEN 7.5, phentermine 7.5 mg; TPM ER 46, topiramate extended-release 46 mg.
oby20584-sup-0002-suppinfo02.docx33KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.